object
inappropri
use
antibiot
associ
develop
antimicrobi
resist
respiratori
infect
often
difficult
differenti
viral
bacteri
infect
empir
treatment
common
enhanc
viral
test
expect
clarifi
clinic
decisionmak
reduc
prescript
antibacteri
agent
impact
inform
patient
care
unclear
method
conduct
random
control
clinic
trial
involv
adult
respiratori
symptom
fever
chest
pain
poor
gener
condit
emerg
unit
tertiari
hospit
multiplex
pcr
result
patient
avail
hour
intervent
group
remain
patient
avail
day
control
group
primari
outcom
measur
durat
hospit
consumpt
antibiot
within
day
enrol
result
patient
respiratori
symptom
studi
entri
respiratori
viru
detect
mean
durat
hospit
day
sd
intervent
group
day
sd
control
group
differ
ci
p
mean
day
antibiot
day
sd
intervent
group
day
sd
control
group
differ
ci
p
conclus
multiplex
pcr
test
respiratori
virus
result
avail
within
hour
reduc
consumpt
bacteri
antibiot
length
hospit
stay
adult
present
respiratori
symptom
fever
chest
pain
reduc
gener
condit
acut
care
e
saarela
clin
microbiol
infect
viral
respiratori
infect
rang
common
cold
sever
lifethreaten
diseas
especi
immunocompromis
individu
differenti
viral
bacteri
respiratori
tract
infect
mere
ground
clinic
symptom
sign
challeng
may
lead
excess
use
antibiot
risk
increas
antimicrobi
resist
cost
nosocomi
infect
includ
clostridium
difficil
respiratori
virus
play
role
pathogenesi
pneumonia
independ
togeth
bacteria
likewis
viral
infect
exacerb
asthmat
symptom
chronic
obstruct
pulmonari
diseas
nucleic
acid
amplificationbas
method
shown
provid
rapid
accur
specif
diagnos
respiratori
viral
infect
rapid
viral
diagnost
increas
cost
method
clear
clinic
impact
justifi
use
identif
influenza
viru
reduc
number
hospit
admiss
length
hospit
durat
antimicrobi
medic
evid
regard
impact
test
respiratori
virus
limit
set
test
random
control
trial
whether
activ
use
multiplex
respiratori
viru
pcr
test
reduc
use
antimicrobi
medic
adult
patient
acut
care
hypothesi
rapid
viral
diagnost
reduc
antibiot
consumpt
length
hospit
stay
random
clinic
trial
involv
adult
enter
intern
medicin
emerg
unit
conduct
oulu
univers
hospit
septemb
octob
tertiari
hospit
bed
emerg
depart
work
hour
day
studi
mainli
antigen
test
influenza
viru
use
offer
opportun
particip
clinic
trial
emerg
room
patient
older
year
respiratori
infect
symptom
cough
rhiniti
short
breath
sore
throat
b
fever
c
c
chest
pain
poor
gener
condit
unknown
reason
appli
exclus
criteria
possibl
particip
inform
studi
train
nurs
work
offic
hour
weekday
obtain
inform
consent
nurs
took
nasal
swab
viral
detect
patient
randomli
alloc
two
group
upon
enrol
rapid
viral
diagnost
group
intervent
group
delay
viral
diagnost
group
control
group
attend
physician
receiv
viral
result
intervent
group
within
hour
except
sampl
obtain
friday
result
avail
next
offic
day
wherea
viral
result
control
group
receiv
day
sampl
patient
random
biostatistician
group
permut
block
four
eight
fig
sampl
opaqu
envelop
correspond
numer
order
open
reveal
group
patient
belong
detect
carriag
rate
respiratori
virus
also
collect
nasal
swab
patient
enter
intern
medicin
emerg
unit
without
respiratori
symptom
nasal
swab
sampl
obtain
use
copan
floq
analys
microbiolog
laboratori
nordlab
oulu
multiplex
realtim
pcr
method
ii
detect
seegen
seoul
korea
detect
rang
respiratori
virus
adenoviru
bocaviru
coronaviru
enteroviru
influenza
ab
viru
metapneumoviru
parainfluenza
viru
rhinoviru
respiratori
syncyti
ab
viru
attend
clinician
access
viral
test
result
accord
group
intervent
control
via
webbas
system
use
routin
clinic
work
decid
upon
treatment
patient
independ
protocol
approv
ethic
committe
northern
ostrobothnia
hospit
district
oulu
finland
trial
regist
number
clinicaltrialscom
databas
nurs
collect
systemat
data
patient
comorbid
current
medic
symptom
entri
follow
week
later
mean
questionnair
durat
symptom
addit
medic
care
need
review
medic
record
followup
time
extract
data
comorbid
cours
diseas
durat
antibiot
medic
length
hospit
durat
intens
care
microbiolog
radiolog
find
record
number
deceas
particip
ascertain
nation
popul
regist
statist
finland
total
cost
patient
hospit
stay
obtain
hospit
administr
cost
use
multiplex
pcr
method
respiratori
viral
detect
per
test
intervent
group
per
test
control
group
includ
hospit
cost
case
intervent
group
wherea
detect
cost
control
group
cover
research
grant
includ
analysi
antimicrobi
consumpt
defin
use
antibacteri
agent
ascertain
medic
record
nation
electron
prescript
databas
inform
provid
particip
way
knew
precis
durat
cours
antibiot
treatment
remain
cours
use
estim
durat
day
prophylact
antibiot
exclud
analysi
primari
outcom
measur
durat
hospit
antibiot
consumpt
durat
hospit
defin
number
day
hospit
within
month
random
antimicrobi
consumpt
defin
number
day
antibiot
number
defin
daili
dose
bacteri
antibiot
within
month
enrol
also
report
proport
patient
receiv
antibiot
treatment
within
day
outcom
also
analys
first
day
viral
result
avail
patient
intervent
group
patient
control
group
secondari
outcom
measur
number
radiolog
examin
total
cost
hospit
treatment
diagnost
procedur
furthermor
compar
number
patient
requir
intens
care
die
follow
appropri
sampl
size
calcul
use
proport
patient
receiv
antimicrobi
treatment
follow
primari
outcom
measur
estim
proport
patient
regard
absolut
reduct
proport
patient
receiv
antibiot
intervent
group
clinic
signific
chang
gain
power
type
error
one
would
need
particip
group
achiev
decid
recruit
particip
two
proport
compar
use
standard
normal
deviat
test
differ
togeth
ci
report
durat
antibiot
treatment
compar
use
student
test
mean
differ
ci
mean
differ
report
analys
perform
follow
intentiontotreat
principl
use
imb
spss
statist
version
ibm
corp
armonk
ny
usa
statsdirect
version
statsdirect
ltd
birkenhead
uk
statist
program
total
elig
patient
includ
trial
randomli
alloc
intervent
group
control
group
fig
group
compar
term
age
comorbid
tabl
intervent
group
least
one
respiratori
symptom
entri
control
group
number
onethird
patient
immunosuppress
group
patient
intervent
group
hospit
patient
control
group
respiratori
viru
detect
patient
intervent
group
control
group
tabl
one
patient
rhinoviru
coronaviru
sampl
other
one
viru
control
group
without
respiratori
symptom
patient
posit
viru
find
total
patient
admit
oulu
univers
hospit
mean
durat
hospit
day
sd
intervent
group
day
sd
differ
ci
control
group
tabl
mean
durat
antibiot
treatment
studi
patient
within
month
day
sd
intervent
group
day
sd
control
group
differ
ci
statist
signific
differ
group
antibiot
consumpt
mean
defin
daili
dose
sd
fig
first
day
patient
group
receiv
antibiot
treatment
tabl
mean
number
radiolog
examin
sd
intervent
group
sd
control
group
differ
ci
statist
signific
differ
group
mean
total
cost
hospit
treatment
per
patient
higher
sd
intervent
group
control
group
sd
differ
ci
mean
cost
radiolog
examin
sd
versu
sd
differ
ci
laboratori
expens
also
higher
intervent
group
rememb
cost
multiplex
pcr
test
includ
laboratori
cost
case
intervent
group
control
group
abbrevi
copd
chronic
obstruct
pulmonari
diseas
intervent
group
c
control
group
rsv
respiratori
syncyti
viru
bocaviru
also
test
found
data
n
patient
radiolog
confirm
pneumonia
b
patient
acut
exacerb
asthma
chronic
obstruct
pulmonari
diseas
c
one
patient
two
virus
sampl
altogeth
n
patient
intervent
group
n
control
group
requir
treatment
intens
care
unit
particip
die
follow
receiv
antibiot
intervent
group
control
group
tabl
antibiot
resist
recogn
major
problem
worldwid
urgent
need
find
way
reduc
use
antibiot
target
better
gain
best
possibl
benefit
lowest
risk
individu
societi
activ
diagnosi
respiratori
pathogen
propos
one
potenti
solut
problem
howev
random
control
trial
knowledg
result
multiplex
respiratori
viru
test
reduc
antimicrobi
consumpt
adult
acut
care
sixtyfour
per
cent
particip
intervent
control
group
receiv
antibiot
followup
period
differ
antibiot
day
defin
daili
dose
durat
hospit
care
group
sever
random
studi
aim
reduc
antibiot
consumpt
mean
improv
diagnost
conduct
recent
year
one
random
control
trial
uk
adult
patient
present
hospit
acut
respiratori
ill
fever
random
two
group
either
molecular
pointofcar
test
respiratori
virus
routin
care
patient
group
receiv
antibiot
mean
durat
antibiot
remain
unchang
also
viral
detect
combin
serum
procalcitonin
pct
measur
algorithm
interpret
pct
result
provid
signific
differ
antibiot
use
howev
subgroup
analysi
random
control
trial
conduct
individu
nonpneumon
lower
respiratori
tract
infect
us
commun
hospit
show
shorter
durat
antibiot
treatment
algorithmadher
patient
fewer
patient
posit
viral
test
low
pct
valu
discharg
antibiot
larg
random
trial
patient
suspect
lower
respiratori
tract
infect
cover
us
urban
academ
hospit
obtain
result
differ
day
antibiot
advers
event
standard
care
group
intervent
group
addit
viral
test
pct
measur
provid
grade
recommend
antibiot
use
base
pct
level
canadian
quasiexperiment
beforeandaft
studi
combin
virolog
test
antimicrobi
stewardship
intervent
decreas
mean
day
antibiot
note
compar
previou
year
without
counsel
physician
seem
respond
less
posit
viral
result
influenza
reli
radiograph
find
decid
antibiot
treatment
shown
prospect
observ
studi
conduct
canadian
tertiari
hospit
reason
intervent
fail
reduc
antibiot
acut
ill
adult
may
due
clinician
anxieti
face
poor
outcom
lower
respiratori
tract
infect
sixth
common
caus
death
highincom
countri
report
influenza
pneumonia
caus
death
annual
usa
observ
studi
medicar
patient
age
year
mortal
among
hospit
individu
communityacquir
pneumonia
incid
pneumonia
rose
fivefold
mortal
doubl
age
increas
year
year
secondari
analysi
epic
studi
inhospit
death
pneumonia
patient
evalu
note
patient
die
tertiari
hospit
least
year
old
least
two
comorbid
mani
patient
intern
medicin
emerg
unit
belong
highrisk
group
fact
proport
patient
viru
detect
nasal
swab
low
larg
explain
definit
popul
recruit
patient
respiratori
infect
symptom
also
patient
chest
pain
poor
gener
condit
see
whether
respiratori
virus
play
role
condit
evalu
whether
viral
test
part
routin
diagnost
subgroup
posit
result
howev
patient
test
influenza
respiratori
viru
detect
influenzalik
symptom
associ
posit
viru
detect
studi
well
even
though
e
particip
asthma
chronic
obstruct
pulmonari
diseas
viru
detect
true
e
individu
acut
coronari
syndrom
suggest
target
test
patient
respiratori
infect
symptom
respiratori
comorbid
would
probabl
benefici
chose
test
impact
rapid
viral
diagnost
reduc
antimicrobi
consumpt
acut
sever
ill
adult
tertiari
hospit
due
extrem
high
antibiot
consumpt
patient
antimicrobi
resist
increas
problem
least
europ
burden
infect
antibioticresist
bacteria
highest
infant
peopl
age
year
threat
poor
outcom
particularli
present
elderli
strength
studi
random
studi
design
larg
sampl
size
broad
panel
virus
high
qualiti
data
due
collect
differ
site
inform
larg
popul
provid
statist
power
detect
differ
group
seri
serv
well
repres
reallif
situat
emerg
room
conveni
nasal
sampl
shown
differ
compar
nasopharyng
swab
influenza
viru
detect
outcom
measur
antibiot
consumpt
clinic
relev
topic
anyplex
ii
multiplex
pcr
detect
method
repres
highest
qualiti
diagnost
avail
time
sensit
test
one
limit
studi
even
intervent
group
viral
detect
result
receiv
hour
sampl
inform
avail
primari
evalu
patient
concern
particularli
individu
discharg
home
emerg
room
low
number
virus
may
also
consid
limit
partial
due
except
low
incid
viral
epidem
studi
annual
variat
sever
viral
outbreak
wellknown
phenomenon
could
control
clinic
trial
extend
studi
period
sever
year
finland
countri
fairli
low
antibiot
consumpt
effect
might
promin
differ
set
conclus
multiplex
respiratori
viru
test
result
avail
within
hour
reduc
consumpt
antibiot
random
control
trial
note
pointofcar
test
provid
multiplex
respiratori
pathogen
result
directli
emerg
room
use
would
interest
topic
investig
futur
author
declar
compet
interest
relat
studi
work
support
research
foundat
pulmonari
diseas
finland
grant
northern
ostrobothnia
hospit
district
finland
